Sep 24, 09
|
| NEW STORY |
| 11:02 ET |
Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
|
|
Aug 25, 09
|
| 11:49 ET |
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
|
|
Jan 15, 09
|
| 10:00 ET |
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
|
|
Oct 28, 08
|
| 12:00 ET |
Peptimmune Presentations at Upcoming Events
|
|
Sep 16, 08
|
| 13:57 ET |
Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
|
|
Jul 30, 08
|
| 12:30 ET |
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
|
|
Jul 16, 08
|
| 11:23 ET |
Peptimmune Announces the Second Close of Series D Private Financing
|
|
Jun 17, 08
|
| 06:00 ET |
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
|
|
Jun 09, 08
|
| 13:00 ET |
Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
|
|
Mar 18, 08
|
| 14:30 ET |
Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
|
|
Jan 17, 08
|
| 10:38 ET |
Peptimmune Announces First Close of Series D Private Financing
|
|
Oct 03, 07
|
| 08:00 ET |
Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
|
|
Sep 18, 07
|
| 08:00 ET |
Peptimmune Appoints Fredric Price as Chairman and Reorganizes its Board of Directors
|
|
Feb 09, 07
|
| 08:00 ET |
Peptimmune to Provide a Progress Report on the Company's Clinical and Non-Clinical Programs.
|
|
Nov 09, 06
|
| 08:00 ET |
Peptimmune and Orphan Europe Partner to Develop Specific Immunotherapy for Life-Threatening Skin Disease
|
|
Jul 15, 05
|
| 08:15 ET |
Peptimmune Closes $20.4 Million Series C Private Financing
|
|
May 10, 05
|
| 10:09 ET |
Peptimmune Announces Two Additions to Management Team
|
|
Jan 24, 05
|
| 14:06 ET |
Peptimmune to Present at Piper Jaffray Health Care Conference in New York City
|
|
Nov 02, 04
|
| 09:11 ET |
Peptimmune Announces Promotion of Thomas P. Mathers to CEO
|
|
Aug 09, 04
|
| 09:41 ET |
Peptimmune Announces Start of Phase I Trial for Obesity
|
|
May 10, 04
|
| 08:49 ET |
Peptimmune is Granted Exclusive License from Genzyme to Develop and Commercialize Treatment for Metabolic Diseases including Obesity
|
|